Agreement will support the development and commercialization of non-opioid therapy for postsurgical pain control
IRVINE, Calif., November 4, 2025 – A team from Knobbe Martens advised Pacira BioSciences, Inc. in an exclusive worldwide license and collaboration agreement with AmacaThera for the development and commercialization of AMT-143, a novel long-acting formulation of the non-opioid analgesic ropivacaine for postsurgical pain control.
Under the terms of the agreement, Pacira will fund clinical development through to commercial launch and the companies will collaborate on Phase 2 clinical development.
The Knobbe Martens team who advised Pacira on the intellectual property aspects of the deal included Jane Dai, Ph.D. and Michelle Ziperstein, Ph.D.
More information on the agreement can be found here.
Earlier this year, Knobbe Martens guided Pacira BioSciences in the acquisition of the remaining equity stake of GQ Bio Therapeutics GmbH.
About Knobbe Martens
Knobbe Martens protects the ideas that drive innovation and propel our world forward. As a leading intellectual property and technology law firm, clients worldwide rely on us to safeguard their products, brands, and technologies through strategic counsel and high-impact litigation. With offices across the U.S., our lawyers and technology specialists collaborate to deliver tailored solutions for clients ranging from multinational corporations to start-ups and emerging companies at every stage. Discover more at www.knobbe.com.
Subscribe for News and Updates
